Acute myeloid leukemia (AML) is a heterogeneous and clonal disorder of the blood-forming
myeloid cells, characterized by an aberrant proliferation and impaired differentiation …

Multidrug resistance (MDR) is a major reason for the failure of acute myeloid leukemia
(AML) therapy. Agents that reverse MDR and sensitize AML cells to chemotherapy are of …

Acute myeloid leukemia (AML) arises secondary to lesions that disrupt normal myelopoiesis.
Despite recent advances in chemotherapy, the 5‐year survival rate is poor (~ 50%) due to …

Introduction: Over the last years, there has been a tremendous increase in understanding
acute myeloid leukemia (AML) biology and a great effort has been taken in order to improve …

The drug efflux pump ABCB1 (ATP binding cassette subfamily B member 1) confers
chemotherapy resistance in acute myeloid leukemia (AML). We recently identified an …

Despite recent advances, prognosis of acute myeloid leukemia (AML) remains
unsatisfactory due to poor response to therapy or relapse. Among causes of resistance, over …

11.1. Introduction 11.2. MDR 11.2. 1. Prognostic impact of ABCB1 phenotype in acute
leukemias 11.2. 2. Clinical trials targeting ABCB1 11.2. 3. Therapeutic strategies targeting …

Introduction To date, no chemoresistance predictors are included in acute myeloid
leukaemia (AML) prognostic scoring systems to distinguish responding and refractory AML …

Despite the progress in the knowledge of disease pathogenesis and the identification of
many molecular markers as potential targets of new therapies, the cure of acute myeloid …

ABCB1 is a member of the ATP binding cassette transporter family and high ABCB1 activity
is considered as a poor prognostic factor in acute myeloid leukemia (AML) treated with …